Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. META

Go back to Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08

February 28, 2023 4:37 PM EST

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

... More